Contact Us | Print Page | Sign In | Register
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 1 of 11
1  |  2  |  3  |  4  |  5  |  6  >   >>   >| 

CMSC Industry News for MS (INforMS)
Friday, June 28, 2019   (0 Comments - view/add)
CMSC INforMS: Alexion’s Soliris gets new, and lucrative, rare disease indication »
June 28, 2019   (This news originally appeared in PharmaPhorum Website at https://phar...
Tuesday, June 25, 2019
CMSC INforMS: Kessler researchers explore social cognitive deficits in progressive MS »
Study by MS research team finds evidence for differential effects of progressive MS on cognitive and affective Theory of M...
Monday, June 24, 2019
CMSC INforMS: CMSC, MS Non-Profits and Polar Products recognizes over 20 years of progress »
  CMSC, MS Non-Profits and Polar Products recognizes over 20 years of progress in the holistic approach to MS sympto...
Saturday, June 22, 2019
CMSC INforMS: June Halper Outlines the Biggest Management Challenges in Multiple Sclerosis »
The biggest clinical challenges that we have in treating multiple sclerosis are 2-fold, explained June Halper, MSN, APN-C,...
Saturday, June 22, 2019
CMSC INforMS: Billings Clinic hosts its first Multiple Sclerosis Health and Well-Being Symposium »
The Billings Clinic hosted its first Multiple Sclerosis Health and Well-Being Symposium. It was a day-long educational sem...
Thursday, June 13, 2019
CMSC INforMS: Study Moves Closer to Identifying Cause of Multiple Sclerosis »
A study by the University of British Columbia made a scientific advance that researchers hope will lead to the development...
Thursday, June 13, 2019
CMSC INforMS: DELIVER-MS Trial Recruiting RRMS Patients to Help Improve Treatment Decision-making »
A clinical trial based at the Cleveland Clinic and the University of Nottingham , U.K., is recruiting patients with re...
Wednesday, May 15, 2019
CMSC INforMS: UCLA researchers work to advance treatment targeting source of multiple sclerosis »
UCLA researchers are developing the first multiple sclerosis treatment that could target the cause of the disease, instead...
Wednesday, May 8, 2019
CMSC INforMS: Press Release - Genentech Presenting New Ocrevus (Ocrelizumab) Data at AAN Meeting »
Genentech to Present New OCREVUS (ocrelizumab) Data Analyses Showing Significant Reduction of Disability Progression in Re...
Thursday, May 2, 2019
CMSC INforMS: MSAA Recognizes Ten Years of Artwork from Individuals with Multiple Sclerosis »
Each year, the Multiple Sclerosis Association of America's Art Showcases provide the opportunity for artists with multiple...
Tuesday, April 30, 2019
CMSC INforMS: FDA Approves MAVENCLAD® (Cladribine) Tablets »
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment...
Friday, April 19, 2019
CMSC INforMS: OHSU doctors part of 'breakthrough' research on treating multiple sclerosis »
PORTLAND, Ore. ( KATU ) – They're calling it a potential game-changer. Doctors at Oregon Health and Science Universit...
Monday, April 15, 2019
CMSC INforMS: Anne Cross, Neurologist w/Pioneering Work into B-cells/MS, Awarded John Dystel Prize »
This year’s John Dystel Prize for Multiple Sclerosis Research is being awarded to Anne H. Cross, a neurologist and MS ch...
Friday, March 29, 2019   (0 Comments - view/add)
CMSC INforMS: Novartis gets FDA approval for Mayzent (siponimod), the first oral drug to treat SPMS »
EAST HANOVER, N.J., March 27, 2019 /PRNewswire/ --Novartis today announced that the US Food and Drug Administration (FDA)...
Wednesday, March 27, 2019
CMSC INforMS: Novartis receives FDA approval for MAYZENT (siponimod) »
- Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multip...
Tuesday, March 26, 2019
CMSC INforMS: Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis »
Brief Summary: Primary Objective: To determine the efficacy of SAR442168 in reducing the number of new brain lesi...
Thursday, March 14, 2019
CMSC INforMS: BrainStorm Announces First Patient in Phase 2 Clinical Trial Progressive MS »
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS Enrollment Announced During MS A...
Tuesday, February 19, 2019
CMSC INforMS: Depression, Psychological Distress Symptoms Affect MS Patients’ Quality of Life »
Depression and psychological distress symptoms can have a huge effect on the way multiple sclerosis (MS) patients view...
Tuesday, December 18, 2018   (0 Comments - view/add)
CMSC INforMS: FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive MS »
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of inn...
Friday, October 12, 2018
CMSC INforMS: Positive Late-Breaking Phase II Data Evaluating Investigational Oral Therapy, »
Positive Late-Breaking Phase II Data Evaluating Investigational Oral Therapy, Evobrutinib in RMS   Fir...
Thursday, October 11, 2018
CMSC INforMS: TG Therapeutics, Inc. Announces Final Phase 2 MS Data Presentation at ECTRIMS »
Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial   ECTRIMS data review conf...
Wednesday, October 10, 2018
CMSC INforMS: Novartis announces FDA filing acceptance of siponimod (BAF312) »
Novartis announces FDA filing acceptance of siponimod (BAF312), the first and only oral drug shown to delay disability pro...
Wednesday, October 10, 2018
CMSC INforMS: Press Release - New Efficacy and Safety Data on MS Portfolio to be Presented »
New Efficacy and Safety Data on MS Portfolio to be Presented at ECTRIMS 2018   Late-breaking Phase I...
Wednesday, October 10, 2018
CMSC INforMS: Press Release - Ocrevus data show early initiation reduces progression »
PRESS RELEASE: OCREVUS (OCRELIZUMAB) DATA SHOW EARLY INITIATION OF TREATMENT REDUCES DISABILITY PROGRESSION OVER FIVE YEAR...
Wednesday, September 12, 2018   (0 Comments - view/add)
CMSC INforMS: Novartis announces PARADIGMS study demonstrating benefit of Gilenya® »
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children...
Wednesday, September 5, 2018
CMSC INforMS: Researchers Identify New Subtype of Multiple Sclerosis »
Researchers have discovered a new subtype of multiple sclerosis (MS), providing a better understanding of the disease and...
Wednesday, August 29, 2018
CMSC INforMS: MRI Tests May Help Doctors Predict MS Progression in Patients »
Researchers may have figured out how to use information from these imaging tests to determine what type of multiple sclero...
Thursday, August 9, 2018   (0 Comments - view/add)
CMSC INforMS: Researchers Have a New Theory About What May Cause Multiple Sclerosis »
When the following headline in the Australian newspaper the Herald Sun caught my eye recently, I was cautiously intrig...
Monday, July 30, 2018   (0 Comments - view/add)
CMSC INFORMS: FDA Accepts File for Cladribine Tablets as Potential Tx for Relapsing Forms of MS »
PDF   ROCKLAND, Mass., July 30, 2018 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Ger...
Tuesday, July 3, 2018
CMSC INforMS: Temperament Can Play a Big Role in Quality of Life with MS »
Researchers say if a person with multiple sclerosis is irritable or anxious, it can make overcoming the obstacles of their...
Thursday, June 14, 2018
CMSC INforMS: PRESS RELEASE: GENENTECH ANNOUNCES NEW OCREVUS (OCRELIZUMAB) DATA FOR PPMS »
PRESS RELEASE: GENENTECH ANNOUNCES NEW OCREVUS (OCRELIZUMAB) DATA ON LONG-TERM DISABILITY BENEFITS IN PRIMARY PROGRESSIVE...
Tuesday, May 1, 2018   (0 Comments - view/add)
CMSC INforMS: AAN Publishes Guideline on Disease-modifying Therapies for MS »
The AAN published a new guideline, Practice Guideline: Disease-modifying Therapies for Adults with Multiple Sclerosis, in...
Tuesday, May 1, 2018
CMSC INforMS: TREAT-MS »
Dr. Scott Newsome and Dr. Ellen Mowry are pleased to announce the launch of their TREAT-MS trial at Hopkins. They will be...
Wednesday, April 25, 2018
CMSC INforMS: NEW OCREVUS (OCRELIZUMAB) DATA DEMONSTRATE REDUCTIONS IN ACTIVITY & PROGRESSION IN RMS »
We are pleased to announce that  new OCREVUS® (ocrelizumab) data were presented at the 70th American Academy of Neur...
Friday, March 23, 2018   (0 Comments - view/add)
CMSC INforMS: Phase III data in The Lancet show Novartis outcomes in secondary progressive MS »
·   EXPAND shows oral siponimod (BAF312) is the first investigational disease-modifying therapy in a large trial t...

Displaying page 1 of 11
1  |  2  |  3  |  4  |  5  |  6  >   >>   >| 

The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275

info@mscare.org